Mediwound (MDWD) versus Kadmon (KDMN) Critical Review

Mediwound (NASDAQ: MDWD) and Kadmon (NYSE:KDMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility & Risk

Mediwound has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Kadmon has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mediwound and Kadmon, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediwound 0 0 5 0 3.00
Kadmon 1 1 2 0 2.25

Mediwound presently has a consensus price target of $9.80, suggesting a potential upside of 110.75%. Kadmon has a consensus price target of $9.75, suggesting a potential upside of 178.57%. Given Kadmon’s higher probable upside, analysts plainly believe Kadmon is more favorable than Mediwound.

Valuation & Earnings

This table compares Mediwound and Kadmon’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mediwound $1.56 million 80.63 -$18.88 million ($0.98) -4.74
Kadmon $26.06 million 10.56 -$208.75 million ($1.75) -2.00

Mediwound has higher earnings, but lower revenue than Kadmon. Mediwound is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

29.5% of Mediwound shares are owned by institutional investors. Comparatively, 51.9% of Kadmon shares are owned by institutional investors. 8.4% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Mediwound and Kadmon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mediwound -904.26% -246.58% -39.43%
Kadmon -555.91% N/A -124.91%


Kadmon beats Mediwound on 7 of the 13 factors compared between the two stocks.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Kadmon Company Profile

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply